Cargando…

Solubility enhancement studies on lurasidone hydrochloride using mixed hydrotropy

Low aqueous solubility is a major problem faced during formulation development of new drug molecules. Lurasidone HCl (LRD) is an antipsychotic agent specially used in the treatments of schizophrenia and is a good example of the problems associated with low aqueous solubility. Lurasidone is practical...

Descripción completa

Detalles Bibliográficos
Autores principales:	Madan, Jyotsana R., Pawar, Kiran T., Dua, Kamal
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Medknow Publications & Media Pvt Ltd 2015
Materias:	Original Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4381388/ https://www.ncbi.nlm.nih.gov/pubmed/25838997 http://dx.doi.org/10.4103/2230-973X.153390

Ejemplares similares

Solubility Enhancement of a Poorly Water-Soluble Drug Using Hydrotropy and Mixed Hydrotropy-Based Solid Dispersion Techniques
por: Abdullah Ali, Hezha, et al.
Publicado: (2022)

Mixed Hydrotropy: Novel Science of Solubility Enhancement
por: Maheshwari, R. K., et al.
Publicado: (2011)

Lurasidone hydrochloride
por: Zhang, Hua, et al.
Publicado: (2012)

Improving Lurasidone Hydrochloride’s Solubility and Stability by Higher-Order Complex Formation with Hydroxypropyl-β-cyclodextrin
por: Gamboa-Arancibia, María Elena, et al.
Publicado: (2023)

Influence of the pK(a) Value of Cinnamic Acid and P-Hydroxycinnamic Acid on the Solubility of a Lurasidone Hydrochloride-Based Coamorphous System
por: Hu, Yi, et al.
Publicado: (2021)

Development and evaluation of in situ gel of pregabalin
por: Madan, Jyotsana R, et al.
Publicado: (2015)

Development and evaluation of solid lipid nanoparticles of mometasone furoate for topical delivery
por: Madan, Jyotsana R, et al.
Publicado: (2014)

Formulation and In Vitro Evaluation of Casein Nanoparticles as Carrier for Celecoxib
por: Madan, Jyotsana R., et al.
Publicado: (2020)

TULIP study: Trail of Lurasidone in bipolar disorder in Pakistan()
por: Khan, Nasar, et al.
Publicado: (2021)

Antipsychotic treatments; focus on lurasidone
por: Sumiyoshi, Tomiki
Publicado: (2013)

Lurasidone-induced Oculogyric Crisis
por: Das, Soumitra, et al.
Publicado: (2017)

Lurasidone-induced Parkinsonism and Hyperprolactinemia
por: Suthar, Navratan, et al.
Publicado: (2019)

Lurasidone in treatment of manic episode
por: Sánchez-Rivero, I.
Publicado: (2022)

Lurasidone for the Treatment of Irritability Associated with Autistic Disorder
por: Loebel, Antony, et al.
Publicado: (2015)

Practical Guidance on the Use of Lurasidone for the Treatment of Adults with Schizophrenia
por: Javed, Afzal, et al.
Publicado: (2019)

Clinical potential of lurasidone in the management of schizophrenia
por: Samalin, Ludovic, et al.
Publicado: (2011)

Critical appraisal of lurasidone in the management of schizophrenia
por: Caccia, Silvio, et al.
Publicado: (2012)

Lurasidone Improves Psychopathology and Cognition in Treatment-Resistant Schizophrenia
por: Meltzer, Herbert Y., et al.
Publicado: (2020)

Lurasidone in the treatment of schizophrenia: a 6-week, placebo-controlled study
por: Ogasa, Masaaki, et al.
Publicado: (2012)

The clinical utility of lurasidone in schizophrenia: patient considerations
por: Harvey, Philip D
Publicado: (2015)

Lurasidone as a potential therapy for bipolar disorder
por: Woo, Young Sup, et al.
Publicado: (2013)

Identification of clinical phenotypes in schizophrenia: the role of lurasidone
por: Riva, Marco Andrea, et al.
Publicado: (2021)

Lurasidone for the treatment of schizophrenia in adult and paediatric populations
por: Guilera, Teresa, et al.
Publicado: (2023)

Lurasidone-induced mania: A case report
por: Fernández, T., et al.
Publicado: (2022)

Porous Microparticles Containing Raloxifene Hydrochloride Tailored by Spray Freeze Drying for Solubility Enhancement
por: Hadipour Moghaddam, Seyyed Pouya, et al.
Publicado: (2018)

Cost-Utility Analysis of Lurasidone Versus Aripiprazole in Adults with Schizophrenia
por: Rajagopalan, Krithika, et al.
Publicado: (2016)

Lurasidone for the treatment of bipolar depression: an evidence-based review
por: Franklin, Rachel, et al.
Publicado: (2015)

Management of bipolar I depression: clinical utility of lurasidone
por: Findlay, Lillian Jan, et al.
Publicado: (2015)

Schizophrenia relapse, patient considerations, and potential role of lurasidone
por: Citrome, Leslie
Publicado: (2016)

Severe Extrapyramidal Syndrome Caused by Lurasidone Low Dose
por: Das, Soumitra, et al.
Publicado: (2018)

Lurasidone-induced anemia: Is there a need for hematological monitoring?
por: Kirpekar, Vivek C., et al.
Publicado: (2019)

Risperidone-induced retrograde ejaculation and lurasidone may be the alternative
por: Shanmugasundaram, Natarajan, et al.
Publicado: (2019)

Lurasidone Augmentation of Clozapine in Schizophrenia—Retrospective Chart Review
por: Siwek, Marcin, et al.
Publicado: (2023)

Lurasidone for the Treatment of Schizophrenia: Design, Development, and Place in Therapy
por: Miura, Itaru, et al.
Publicado: (2023)

Lurasidone augmentation to clozapine in treatment resistant schizophrenia: A pilot study
por: Arienti, V., et al.
Publicado: (2023)

Weight change during long-term treatment with lurasidone: pooled analysis of studies in patients with schizophrenia
por: Meyer, Jonathan M., et al.
Publicado: (2015)

Efficacy and Safety of Lurasidone in Adolescents with Schizophrenia: A 6-Week, Randomized Placebo-Controlled Study
por: Goldman, Robert, et al.
Publicado: (2017)

Lurasidone in Children and Adolescents with Bipolar Depression Presenting with Mixed (Subsyndromal Hypomanic) Features: Post Hoc Analysis of a Randomized Placebo-Controlled Trial
por: Singh, Manpreet K., et al.
Publicado: (2020)

Update on the development of lurasidone as a treatment for patients with acute schizophrenia
por: Yasui-Furukori, Norio
Publicado: (2012)

Neutropenia with Multiple Antipsychotics Including Dose Dependent Neutropenia with Lurasidone
por: Sood, Shabnam
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_qhq0t12dnrmq877suhi8gle1ku